LONDON, GREATER LONDON, UNITED KINGDOM, May 23, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and children aged 9 years and older.

How does one live with psoriasis? From medication to nutrition (and beyond), Olivia Marks goes in search of clear answers.

Although you may not have heard of enthesitis, the structures in the body affected by the condition are involved in every move you make. Bones and muscles are held together by tendons and ligaments, ...

India Bolton shares her powerful journey of living with guttate psoriasis, from diagnosis in college to managing flares while becoming a mother. In this inspiring video, India opens up about the ...

Results showed 66% of patients treated with icotrokinra achieved an ss-IGA score of 0/1 and 77% achieved a sPGA-G score of 0/1, compared with 11% and 21% receiving placebo, respectively, at week 16.

66% of patients with scalp psoriasis achieved a scalp-specific Investigator's Global Assessment (ss-IGA) c score of 0/1 compared to 11% receiving placebo (P<0.001) at 16 weeks.

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients ...

Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to ...

Researchers reviewed a host of studies investigating diet plans in an effort to guide evidence-based recommendations for patients with psoriasis. Despite limited comprehensive evidence supporting the ...